Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antimetabolites, Antineoplastic
  • Antineoplastic Combined Chemotherapy Protocols
  • Camptothecin
  • Deoxycytidine
  • Pancreatic Neoplasms

abstract

  • Exatecan plus gemcitabine was not superior to gemcitabine alone with respect to overall survival in the first-line treatment of advanced pancreatic cancer.

publication date

  • September 20, 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.07.0201

PubMed ID

  • 16983112

Additional Document Info

start page

  • 4441

end page

  • 7

volume

  • 24

number

  • 27